{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:56:26Z","timestamp":1794315386645,"version":"4.9.0"},"reference-count":235,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.biologicals.2025.101849","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:24:52Z","timestamp":1751379892000},"page":"101849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The past, present and future of blood plasma fractionation"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9770-0499","authenticated-orcid":false,"given":"John","family":"Curling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0804-7463","authenticated-orcid":false,"given":"Albert","family":"Farrugia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3293-7861","authenticated-orcid":false,"given":"Leni","family":"von Bonsdorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2025.101849_bib1","first-page":"629","article-title":"Obituary","volume":"3624","author":"S\u00f8rensen","year":"1939","journal-title":"Nat. No"},{"key":"10.1016\/j.biologicals.2025.101849_bib2","article-title":"Development of the theory of electrolytic dissociation","author":"Arrhenius","year":"1903","journal-title":"Nobel Prize"},{"key":"10.1016\/j.biologicals.2025.101849_bib3","series-title":"Cohn and the development of protein chemistry. Center for blood research","first-page":"15","author":"Surgenor","year":"2002"},{"key":"10.1016\/j.biologicals.2025.101849_bib4","article-title":"The ultracentrifuge","year":"1927","journal-title":"Nobel Prize"},{"key":"10.1016\/j.biologicals.2025.101849_bib5","article-title":"Producing molecular therapeutics from human blood: Edwin Cohn's wartime enterprise","volume":"vol. 6","author":"Creager","year":"1998"},{"key":"10.1016\/j.biologicals.2025.101849_bib6","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1021\/ja01199a051","article-title":"Preparation and properties of serum and plasma proteins. XIII. Crystallization of serum albumins from ethanol-water mixtures","volume":"69","author":"Cohn","year":"1947","journal-title":"J Am Chem Soc 69"},{"key":"10.1016\/j.biologicals.2025.101849_bib7","article-title":"Electrophoresis and adsorption analysis as aids in investigations of large molecular weight substances and their breakdown products","author":"Tiselius","year":"1948","journal-title":"Nobel Prize"},{"issue":"6","key":"10.1016\/j.biologicals.2025.101849_bib8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1085\/jgp.4.6.697","article-title":"Studies in the physical chemistry of the proteins. The solubility of certain proteins at their isoelectric points","volume":"4","author":"Cohn","year":"1992","journal-title":"J Gen Physiol"},{"key":"10.1016\/j.biologicals.2025.101849_bib9","series-title":"Compt. Rend. Trav. Lab. Carlsberg","author":"S\u00f8rensen","year":"1917"},{"key":"10.1016\/j.biologicals.2025.101849_bib10","first-page":"639","article-title":"Proteins as chemical substances and as biological components","volume":"15","author":"Cohn","year":"1939","journal-title":"Bull NY Acad Med"},{"key":"10.1016\/j.biologicals.2025.101849_bib11","series-title":"Blood substitutes and blood transfusion","first-page":"173","article-title":"Properties and functions of the purified proteins of animal and human plasmas","author":"Cohn","year":"1942"},{"key":"10.1016\/j.biologicals.2025.101849_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1098\/rspb.1908.0037","article-title":"Diphtheria antitoxin","volume":"80","author":"Mellanby","year":"1908","journal-title":"Proc R Soc Lond Ser B"},{"key":"10.1016\/j.biologicals.2025.101849_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1085\/jgp.16.2.243","article-title":"Factors involved in the use of organic solvents as precipitating and drying agents of immune sera","volume":"16","author":"Merrill","year":"1932","journal-title":"J Gen Physiol"},{"key":"10.1016\/j.biologicals.2025.101849_bib14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S1369-8486(99)00017-5","article-title":"What blood told dr. Cohn: world war II, plasma fractionation, and the growth of human blood research","volume":"30C","author":"Creager","year":"1999","journal-title":"Studie History Philosophy of Biol Biomed Sci"},{"key":"10.1016\/j.biologicals.2025.101849_bib15","first-page":"47","article-title":"Blood program in world war II. Chapter III. The evolution of the use of whole blood in combat casualties","author":"Kendrick","year":"1964"},{"key":"10.1016\/j.biologicals.2025.101849_bib16","series-title":"Blood program in world war II. Chapter XII the bovine and human albumin programs. Medical department","first-page":"325","author":"Kendrick","year":"1964"},{"key":"10.1016\/j.biologicals.2025.101849_bib17","unstructured":"Cohn EJ. Protein product and process. US Patent 2,390,074 (Dec 4, 1945, continuation from 1940)."},{"key":"10.1016\/j.biologicals.2025.101849_bib18","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1021\/ja01869a032","article-title":"Preparation and properties of serum and plasma proteins. III. Size and charge of proteins separating upon equilibration across membranes with Ethanol\u2014Water mixtures of controlled pH, ionic strength and temperature","volume":"62","author":"Cohn","year":"1940","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.biologicals.2025.101849_bib19","series-title":"Adv in military medicine, science in world war II","first-page":"364","article-title":"The history of plasma fractionation","author":"Cohn","year":"1948"},{"key":"10.1016\/j.biologicals.2025.101849_bib20","series-title":"Cohn and the development of protein chemistry. Center for blood research","first-page":"107","author":"Surgenor","year":"2002"},{"key":"10.1016\/j.biologicals.2025.101849_bib21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/ja01207a034","article-title":"Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids","volume":"68","author":"Cohn","year":"1946","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.biologicals.2025.101849_bib22","series-title":"Blood substitutes and blood transfusion","first-page":"173","article-title":"Properties and functions of the purified proteins of animal and human plasmas","author":"Cohn","year":"1942"},{"key":"10.1016\/j.biologicals.2025.101849_bib23","first-page":"59","article-title":"Blood, blood derivatives and blood substitutes","volume":"88","author":"Cohn","year":"1944","journal-title":"Proc Am Phil Soc"},{"key":"10.1016\/j.biologicals.2025.101849_bib24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/0003-4819-26-3-341","article-title":"The separation of blood into fractions of therapeutic value","volume":"26","author":"Cohn","year":"1947","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.biologicals.2025.101849_bib25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0021-9258(18)43052-9","article-title":"Biophysical studies of blood plasma proteins. III. Recovery of \u03b3-globulin from human blood protein mixtures","volume":"164","author":"Deutsch","year":"1946","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biologicals.2025.101849_bib26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1021\/ja01170a048","article-title":"The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and \u03b21-lipoprotein into sub-fractions of human plasma","volume":"71","author":"Oncley","year":"1949","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.biologicals.2025.101849_bib27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1021\/ja01157a122","article-title":"A system for the separation of the components of human blood: quantitative procedures for the separation of the protein components of human plasma","volume":"72","author":"Cohn","year":"1950","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.biologicals.2025.101849_bib28","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/hlca.19540370327","article-title":"Vereinfachtes Verfahren zur Gewinnung von humanem Albumin und \u03b3-Globulin aus Blutplasma mittels Alkoholf\u00e4llung","volume":"37","author":"Nitschmann","year":"1954","journal-title":"Helv Chem Acta"},{"key":"10.1016\/j.biologicals.2025.101849_bib29","first-page":"414","article-title":"Large scale production of human plasma fractions. Eight years of experience with the alcohol fractionation procedure of nitschmann, kistler and legier","volume":"7","author":"Kistler","year":"1962","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2025.101849_bib30","series-title":"Methods of plasma protein fractionation","first-page":"3","article-title":"Ethanol precipitation","author":"Kistler","year":"1980"},{"key":"10.1016\/j.biologicals.2025.101849_bib31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1423-0410.1972.tb03817.x","article-title":"Precipitation methods in plasma fractionation","volume":"23","author":"Steinbuch","year":"1972","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2025.101849_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/02648725.2000.10647987","article-title":"The use of chromatography to manufacture purer and safer plasma products","volume":"17","author":"Johnston","year":"2000","journal-title":"Biotechnol Genet Eng Rev"},{"key":"10.1016\/j.biologicals.2025.101849_bib33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1423-0410.1963.tb02372.x","article-title":"Concentration and purification of ceruloplasmin from human blood plasma fractions","volume":"8","author":"Bj\u00f6rling","year":"1963","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2025.101849_bib34","first-page":"18","article-title":"Plasma fractionation methods used in Sweden","volume":"23","author":"Bj\u00f6rling","year":"1972","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2025.101849_bib35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1423-0410.1977.tb02240.x","article-title":"A chromatographic procedure for the purification of human plasma albumin","volume":"33","author":"Curling","year":"1977","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2025.101849_bib36","series-title":"Proceedings of the international workshop on technology for protein separation and improvement of blood plasma fractionation","first-page":"269","article-title":"Ion exchange chromatography as a method for large scale purification of albumin","author":"Curling","year":"1977"},{"issue":"4\u20135","key":"10.1016\/j.biologicals.2025.101849_bib37","first-page":"282","article-title":"Chromatographic preparation and in vitro properties of albumin from human plasma","volume":"5","author":"Bergl\u00f6f","year":"1983","journal-title":"J Appl Biochem"},{"key":"10.1016\/j.biologicals.2025.101849_bib38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1423-0410.1972.tb03818.x","article-title":"Fractionation of plasma with polyethylene glycol","volume":"23","author":"Polson","year":"1972","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2025.101849_bib39","series-title":"Methods of plasma protein fractionation","first-page":"57","article-title":"Fractional precipitation of proteins with polyethylene glycol","author":"Hao","year":"1980"},{"key":"10.1016\/j.biologicals.2025.101849_bib40","first-page":"143","article-title":"Development of a process for the preparation of human serum albumin using chromatographic methods","volume":"227","author":"Yap","year":"1993","journal-title":"Biotechnol Blood Prot"},{"key":"10.1016\/j.biologicals.2025.101849_bib41","first-page":"155","article-title":"Design of a large scale chromatographic plant for the purification of human albumin","volume":"227","author":"Micucci","year":"1993","journal-title":"Biotechnol Blood Prot"},{"key":"10.1016\/j.biologicals.2025.101849_bib43","first-page":"3","article-title":"Chromatographic methods of fractionation","volume":"67","author":"Friesen","year":"1987","journal-title":"Develop Biol Standard"},{"key":"10.1016\/j.biologicals.2025.101849_bib44","series-title":"Production of plasma proteins for therapeutic use","first-page":"207","article-title":"Hyperimmune immunoglobulin G","author":"Price","year":"2013"},{"key":"10.1016\/j.biologicals.2025.101849_bib45","first-page":"15","article-title":"Large scale use of spherosil ion exchangers in plasma fractionation","volume":"67","author":"Tayot","year":"1987","journal-title":"Dev Biol Stand"},{"issue":"3","key":"10.1016\/j.biologicals.2025.101849_bib46","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000466742","article-title":"Contributions to the optimal use of human blood","volume":"27","author":"Vogelaar","year":"1974","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2025.101849_bib47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1423-0410.2005.00731.x","article-title":"A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance","volume":"90","author":"Parkkinen","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2025.101849_bib48","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1423-0410.2003.00285.x","article-title":"Properties of a new intravenous immunoglobulin (IGIV-C, 10% produced by viral inactivation with caprylate and column chromatography","volume":"84","author":"Lebing","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2025.101849_bib49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1423-0410.2005.00710.x","article-title":"Viral safety of nanogam, a new 15 nm-filtered liquid immunoglobulin product","volume":"90","author":"Terpstra","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2025.101849_bib50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000357982","article-title":"Development, manufacturing and characterization of a highly purified, liquid immunoglobulin G preparation from human plasma","volume":"41","author":"Laursen","year":"2014","journal-title":"Transfus Med Hemotherapy"},{"key":"10.1016\/j.biologicals.2025.101849_bib51","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/biot.200500037","article-title":"Purification of intravenous immunoglobulin G from human plasma \u2013 aspects of yield and virus safety","volume":"1","author":"Buchacher","year":"2006","journal-title":"Biotechnol J"},{"issue":"16","key":"10.1016\/j.biologicals.2025.101849_bib52","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2217\/imt-2019-0157","article-title":"Manufacturing process optimization of ADMA biologics' intravenous immunoglobulin products, BIVIGAM\u00ae and ASCENIV\u00ae","volume":"11","author":"Wasserman","year":"2019","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.biologicals.2025.101849_bib53","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1423-0410.2010.01345.x","article-title":"Specific protein content of pools of plasma for fractionation from different sources: impact of frequency of donations","volume":"99","author":"Laub","year":"2010","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2025.101849_bib54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21037\/aob.2018.05.03","article-title":"An overview of plasma fractionation","volume":"3","author":"Burnouf","year":"2018","journal-title":"Ann Blood"},{"key":"10.1016\/j.biologicals.2025.101849_bib55","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0003-9861(69)90285-9","article-title":"The isolation of IgG from Mammalian sera with the aid of caprylic acid","volume":"134","author":"Steinbuch","year":"1969","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.biologicals.2025.101849_bib56","first-page":"201","article-title":"Column ion exchange chromatographic production of human immune serum globulin for intravenous use","volume":"48","author":"Friesen","year":"1985","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2025.101849_bib57","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1590\/S0100-879X2000000100004","article-title":"High quality human immunoglobulin G purified from cohn fractions by liquid chromatography","volume":"33","author":"Tanaka","year":"2000","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.biologicals.2025.101849_bib58","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/bp000139d","article-title":"Continuous removal of protein aggregates by annular chromatography","volume":"17","author":"Buchacher","year":"2001","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.biologicals.2025.101849_bib59","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1008170226665","article-title":"New method for the selective capture of antibodies under physiolgical conditions","volume":"9","author":"Guerrier","year":"2000","journal-title":"Bioseparation"},{"key":"10.1016\/j.biologicals.2025.101849_bib60","series-title":"Proceedings of the international workshop on technology for protein separation and improvement of blood plasma fractionation","first-page":"15","article-title":"Technological problems in large-scale plasma fractionation","author":"Rothstein","year":"1977"},{"issue":"2","key":"10.1016\/j.biologicals.2025.101849_bib61","article-title":"Factor VIII manufactured from plasma\u2014the ups and downs, and the up again: a personal journey\u2014part 1: history of the development of plasma-derived factor VIII therapy","volume":"3","author":"Farrugia","year":"2018","journal-title":"Annal Blood"},{"key":"10.1016\/j.biologicals.2025.101849_bib62","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJM196512302732701","article-title":"Production of high-potency concentrates of antihemophilic globulin in a closed-bagsystem","volume":"273","author":"Pool","year":"1965","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.biologicals.2025.101849_bib63","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/BF01630381","article-title":"The use of human AHF (fraction I-0) in haemophilia A","volume":"8","author":"Nilsson","year":"1962","journal-title":"Blut"},{"issue":"1","key":"10.1016\/j.biologicals.2025.101849_bib64","first-page":"8","article-title":"A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography","volume":"60","author":"Burnouf","year":"1991","journal-title":"Vox Sang"},{"issue":"2","key":"10.1016\/j.biologicals.2025.101849_bib65","first-page":"84","article-title":"Immunoaffinity purification of factor VIII","volume":"19","author":"Weinstein","year":"1989","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.biologicals.2025.101849_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/26348535211064621","article-title":"Quality attributes of plasma derived human fibrinogen (Fibrogen-I\u00ae)","volume":"15","author":"Dolia","year":"2021","journal-title":"Plasmatology"},{"issue":"2","key":"10.1016\/j.biologicals.2025.101849_bib67","first-page":"113","article-title":"Contributions to the optimal use of human blood. II. The large-scale preparation of prothrombin complex. A comparison between two methods using the anion exchangers DEAE-cellulose DE 52 and DEAE-sephadex A-50","volume":"25","author":"Heystek","year":"1973","journal-title":"Vox Sang"},{"issue":"2","key":"10.1016\/j.biologicals.2025.101849_bib68","first-page":"118","article-title":"Contributions to the optimal use of human blood. 3. Large-scale preparation of human c1 esterase inhibitor concentrate for clinical use","volume":"26","author":"Vogelaar","year":"1974","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2025.101849_bib69","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0049-3848(74)90001-2","article-title":"Purification of antithrombin III by affinity chromatography","volume":"5","author":"Miller-Andersson","year":"1974","journal-title":"Thromb Res"},{"key":"10.1016\/j.biologicals.2025.101849_bib70","series-title":"Production of plasma proteins for therapeutic use","first-page":"227","article-title":"Alpha1-proteinase inhibtor: the disease, the protein, and commercial production","author":"Lebing","year":"2013"},{"key":"10.1016\/j.biologicals.2025.101849_bib71","first-page":"18","article-title":"Current status and new developments in the production of plasma derivatives","volume":"52","author":"Burnouf","year":"2016","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2025.101849_bib72","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0378-4347(94)00532-A","article-title":"Chromatography in plasma fractionation: benefits and future trends","volume":"664","author":"Burnouf","year":"1995","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.biologicals.2025.101849_bib73","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0165-022X(01)00221-4","article-title":"Affinity chromatography in the industrial purification of plasma proteins for therapeutic use","volume":"49","author":"Burnouf","year":"2001","journal-title":"J Biochem Biophys Methods"},{"key":"10.1016\/j.biologicals.2025.101849_bib74","series-title":"Biopharmaceutical processing. Development, design and implemetation of manufacturing processes","first-page":"207","article-title":"Overview of alternative separation methods in relation to process challenges","author":"Van Alstine","year":"2018"},{"key":"10.1016\/j.biologicals.2025.101849_bib75","article-title":"Securing commitment and control for the supply of plasma derivatives for public health systems. I: a short review of the global landscape","author":"von Bonsdorff","year":"2024","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2025.101849_bib76","series-title":"Production of plasma proteins for therapeutic use","first-page":"31","article-title":"Production and clinical profile of human plasma coagulation factor VIII","author":"Chtourou","year":"2013"},{"key":"10.1016\/j.biologicals.2025.101849_bib77","series-title":"Production of plasma proteins for therapeutic use","first-page":"41","article-title":"Production and clinical profile of human plasma-derived von Willebrand Factor","author":"Chtourou","year":"2013"},{"key":"10.1016\/j.biologicals.2025.101849_bib78","series-title":"Production of plasma proteins for therapeutic use","first-page":"81","article-title":"Factor IX","author":"Grancha","year":"2013"},{"key":"10.1016\/j.biologicals.2025.101849_bib79","first-page":"765","article-title":"Intravenous immunoglobulins: evolution of commercial IVIG preparations","volume":"28","author":"Hooper","year":"2008","journal-title":"Immunol Allergy Clin"},{"key":"10.1016\/j.biologicals.2025.101849_bib80","series-title":"Biopharmaceutical processing. Development, design and implemetation of manufacturing processes","first-page":"857","article-title":"Current manufacturing of human plasma immunoglobulin G","author":"Buchacher","year":"2018"},{"key":"10.1016\/j.biologicals.2025.101849_bib81","series-title":"Rossi's principles of transfusion medicine","first-page":"303","article-title":"The purification of plasma proteins for therapeutic use","author":"Bertolini","year":"2016"},{"key":"10.1016\/j.biologicals.2025.101849_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1253177","article-title":"Cation exchange chromatography removes FXIa from a 10% intravenous immunoglobulin preparation","volume":"10","author":"Kang","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"7563","key":"10.1016\/j.biologicals.2025.101849_bib83","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(68)90527-8","article-title":"Anaphylactoid transfusion reactions associated with anti-IgA","volume":"2","author":"Vyas","year":"1968","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.biologicals.2025.101849_bib84","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaip.2013.05.014","article-title":"Administration of intravenous immunoglobulin to a patient with hypogammaglobulinemia and Anti-IgA antibodies","volume":"1","author":"Lieberman","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.biologicals.2025.101849_bib85","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaci.2011.06.047","article-title":"The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature","volume":"129","author":"Rachid","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.biologicals.2025.101849_bib86","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/ACI.0b013e32834c22da","article-title":"Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose","volume":"11","author":"Berger","year":"2011","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.biologicals.2025.101849_bib87","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1423-0410.2012.01648.x","article-title":"In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations","volume":"104","author":"Dhainaut","year":"2013","journal-title":"Vox Sang"},{"issue":"6","key":"10.1016\/j.biologicals.2025.101849_bib88","volume":"2","author":"Roemisch","year":"2011","journal-title":"WebmedCentral Immun"},{"key":"10.1016\/j.biologicals.2025.101849_bib89","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1111\/trf.13088","article-title":"Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products","volume":"55","author":"Hoefferer","year":"2015","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.biologicals.2025.101849_bib90","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40259-016-0192-3","article-title":"Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) using blood group A- and B-specific immunoaffinity chromatography: Industry-scale assessment","volume":"30","author":"Gerber","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.biologicals.2025.101849_bib91","series-title":"Production of plasma proteins for therapeutic use","first-page":"449","article-title":"The economics of plasma fractionation","author":"Goss","year":"2013"},{"key":"10.1016\/j.biologicals.2025.101849_bib92","series-title":"Global developments in the supply of Ig. The Source, summer","author":"Waller","year":"2007"},{"key":"10.1016\/j.biologicals.2025.101849_bib93","first-page":"86","year":"2023"},{"key":"10.1016\/j.biologicals.2025.101849_bib94","first-page":"261","article-title":"Purification technologies for human plasma albumin","author":"More","year":"1991"},{"key":"10.1016\/j.biologicals.2025.101849_bib95","series-title":"Methods of plasma protein fractionation","first-page":"17","article-title":"The CSVM fractionation process","author":"Foster","year":"1980"},{"key":"10.1016\/j.biologicals.2025.101849_bib96","series-title":"Production of plasma proteins for therapeutic use","first-page":"159","article-title":"Human serum albumin: a multifunctional plasma protein","author":"More","year":"2013"},{"key":"10.1016\/j.biologicals.2025.101849_bib97","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.xphs.2022.03.005","article-title":"Therapeutic solutions of human albumin - the possible effect of process-induced molecular alterations on clinical efficacy and safety","volume":"11","author":"Farrugia","year":"2022","journal-title":"J Pharmaceut Sci"},{"key":"10.1016\/j.biologicals.2025.101849_bib98","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jchromb.2014.08.029","article-title":"Use of mwp HyperCel for polishing of human serum albumin","volume":"969","author":"McCann","year":"2014","journal-title":"J Chromatogr B"},{"issue":"6","key":"10.1016\/j.biologicals.2025.101849_bib99","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/bja\/85.6.887","article-title":"Production of human albumin solution: a continually developing colloid","volume":"85","author":"Matejtschuk","year":"2000","journal-title":"Br J Anaesth"},{"issue":"2","key":"10.1016\/j.biologicals.2025.101849_bib100","first-page":"93","article-title":"Studies on new process procedures in plasma fractionation on an industrial scale. IV. Comparison of two semipermeable membrane systems for the concentration of albumin solutions","volume":"33","author":"Friedli","year":"1977","journal-title":"Vox Sang"},{"issue":"10","key":"10.1016\/j.biologicals.2025.101849_bib101","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.1947.02880270001001","article-title":"Homologous serum jaundice: a problem in the operation of blood banks","volume":"134","author":"Scheinberg","year":"1947","journal-title":"J Am Med Assoc"},{"issue":"2","key":"10.1016\/j.biologicals.2025.101849_bib102","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1172\/JCI101939","article-title":"Chemical, clinical, and immunological studies on the products of human plasma fractionation. xxxvi. inactivation of the virus of homologous serum hepatitis in solutions of normal human serum albumin by means of heat","volume":"27","author":"Gellis","year":"1948","journal-title":"J Clin Investig"},{"key":"10.1016\/j.biologicals.2025.101849_bib103","series-title":"Transfusion microbiology","first-page":"259","article-title":"Fractionated products","author":"Foster","year":"2008"},{"issue":"8","key":"10.1016\/j.biologicals.2025.101849_bib104","first-page":"1145","article-title":"The problem of reducing the danger of serum; hepatitis from blood and blood products","volume":"55","author":"Murray","year":"1955","journal-title":"N Y State J Med"},{"issue":"3","key":"10.1016\/j.biologicals.2025.101849_bib105","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/infdis\/123.3.279","article-title":"Development and persistence of antibody to hepatitis-associated (Australia) antigen in patients with hemophilia","volume":"123","author":"Seeler","year":"1971","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.biologicals.2025.101849_bib106","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2307\/2529402","article-title":"Estimation of the probability of post transfusion hepatitis in hemophilia treatment","volume":"29","author":"Davis","year":"1973","journal-title":"Biometrics"},{"issue":"4902","key":"10.1016\/j.biologicals.2025.101849_bib107","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"issue":"6407","key":"10.1016\/j.biologicals.2025.101849_bib108","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/bmj.287.6407.1754","article-title":"Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients","volume":"287","author":"Fletcher","year":"1983","journal-title":"Br Med J (Clin Res Ed)."},{"issue":"8290","key":"10.1016\/j.biologicals.2025.101849_bib109","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0140-6736(82)91105-9","article-title":"Hepatitis and haemophilia therapy in Australia","volume":"2","author":"Rickard","year":"1982","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.biologicals.2025.101849_bib110","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1111\/j.1538-7836.2006.02213.x","article-title":"The tragic history of AIDS in the hemophilia population, 1982-1984","volume":"4","author":"Evatt","year":"2006","journal-title":"J Thromb Haemostasis"},{"issue":"3","key":"10.1016\/j.biologicals.2025.101849_bib111","doi-asserted-by":"crossref","first-page":"401","DOI":"10.7326\/0003-4819-98-3-401","article-title":"Acquired immune deficiency syndrome: the past as prologue","volume":"98","author":"Curran","year":"1983","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.biologicals.2025.101849_bib112","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1046\/j.1537-2995.1991.31191096183.x","article-title":"Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. The Transfusion safety study group","volume":"31","author":"Busch","year":"1991","journal-title":"Transfusion"},{"issue":"9","key":"10.1016\/j.biologicals.2025.101849_bib113","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1046\/j.1537-2995.2002.00183.x","article-title":"NAT screening of blood and plasma donations: evolution of technology and regulatory policy","volume":"42","author":"Tabor","year":"2002","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.biologicals.2025.101849_bib114","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1365-2516.2004.00911.x","article-title":"Plasma for fractionation: safety and quality issues","volume":"10","author":"Farrugia","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.biologicals.2025.101849_bib115","series-title":"Transfusion medicine: quo vadis? What has been achieved, what is to be expected: proceedings of the jubilee twenty-fifth international symposium on blood transfusion, Groningen","article-title":"Plasma fractionation","author":"Foster","year":"2000"},{"key":"10.1016\/j.biologicals.2025.101849_bib116","first-page":"303","article-title":"Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients","volume":"67","author":"Heimburger","year":"1987","journal-title":"Dev Biol Stand"},{"issue":"8423","key":"10.1016\/j.biologicals.2025.101849_bib117","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(85)91043-8","article-title":"Absence of antibodies to aids virus in haemophiliacs treated with heat-treated factor viii concentrate","volume":"325","author":"Rouzioux","year":"1985","journal-title":"Lancet"},{"issue":"8445","key":"10.1016\/j.biologicals.2025.101849_bib118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0140-6736(85)90055-8","article-title":"Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate","volume":"2","author":"Colombo","year":"1985","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.biologicals.2025.101849_bib119","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1046\/j.1537-2995.1985.25686071422.x","article-title":"Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations","volume":"25","author":"Horowitz","year":"1985","journal-title":"Transfusion"},{"key":"10.1016\/j.biologicals.2025.101849_bib120","first-page":"147","article-title":"Viral safety of solvent-detergent treated blood products","volume":"81","author":"Horowitz","year":"1993","journal-title":"Dev Biol Stand"},{"issue":"3","key":"10.1016\/j.biologicals.2025.101849_bib121","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1537-2995.2001.41030338.x","article-title":"Hemophilia surveillance system project investigators. Risk factors for infection with HBV and HCV in a large cohort of hemophiliac males","volume":"41","author":"Soucie","year":"2001","journal-title":"Transfusion"},{"issue":"4722","key":"10.1016\/j.biologicals.2025.101849_bib122","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/bmj.2.4722.6","article-title":"Homologous serum hepatitis and measles prophylaxis; a report to the medical research council","volume":"2","author":"Cockburn","year":"1951","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.biologicals.2025.101849_bib123","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/infdis\/135.2.252","article-title":"Hepatitis B in subjects treated with a drug containing immunoglobulins","volume":"135","author":"Petrilli","year":"1977","journal-title":"J Infect Dis"},{"issue":"8155","key":"10.1016\/j.biologicals.2025.101849_bib124","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(79)92296-7","article-title":"Transmission of hepatitis B by immune serum globulin","volume":"2","author":"Tabor","year":"1979","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.biologicals.2025.101849_bib125","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0168-8278(91)90076-N","article-title":"Long-term persistence of hepatitis C virus antibodies in a single source outbreak","volume":"13","author":"Dittmann","year":"1991","journal-title":"J Hepatol"},{"issue":"16","key":"10.1016\/j.biologicals.2025.101849_bib126","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199904223401602","article-title":"Clinical outcomes after hepatitis C infection from contaminated Anti-D immune globulin","volume":"340","author":"Kenny-Walsh","year":"1999","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.biologicals.2025.101849_bib127","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1537-2995.1992.32993110753.x","article-title":"Partitioning of hepatitis C virus during cohn-oncley fractionation of plasma","volume":"32","author":"Yei","year":"1992","journal-title":"Transfusion"},{"issue":"7","key":"10.1016\/j.biologicals.2025.101849_bib128","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1046\/j.1537-2995.1994.34794330014.x","article-title":"Detection and characterization of hepatitis C virus RNA in immune globulins","volume":"34","author":"Yu","year":"1994","journal-title":"Transfusion"},{"key":"10.1016\/j.biologicals.2025.101849_bib129","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0149-2918(96)80195-0","article-title":"Intravenous immunoglobulin and hepatitis C virus: an overview of transmission episodes with emphasis on manufacturing data","volume":"18","author":"Yap","year":"1996","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.biologicals.2025.101849_bib130","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0163-4453(87)93096-9","article-title":"The viral safety of intravenous immunoglobulin","volume":"15","author":"Cuthbertson","year":"1987","journal-title":"J Infect"},{"issue":"8356","key":"10.1016\/j.biologicals.2025.101849_bib131","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0140-6736(83)90496-8","article-title":"Non-A, non-B hepatitis from intravenous immunoglobulin","volume":"2","author":"Lane","year":"1983","journal-title":"Lancet"},{"issue":"8481","key":"10.1016\/j.biologicals.2025.101849_bib132","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0140-6736(86)92826-6","article-title":"Intravenous immunoglobulin home treatment for patients with primary immunodeficiency diseases","volume":"1","author":"Ochs","year":"1986","journal-title":"Lancet"},{"issue":"28","key":"10.1016\/j.biologicals.2025.101849_bib133","first-page":"505","article-title":"Epidemiologic notes and reports outbreak of hepatitis C associated with intravenous immunoglobulin administration -- United States, October 1993-June 1994","volume":"43","author":"Schneider","year":"1994","journal-title":"MMWR (Morb Mortal Wkly Rep)"},{"issue":"Suppl B","key":"10.1016\/j.biologicals.2025.101849_bib134","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0149-2918(96)80198-6","article-title":"Intravenous immunoglobulin and hepatitis C virus: the Scandinavian experience","volume":"18","author":"Bj\u00f6rkander","year":"1996","journal-title":"Clin Ther"},{"issue":"8609","key":"10.1016\/j.biologicals.2025.101849_bib135","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0140-6736(88)90138-9","article-title":"Non-A, non-B hepatitis transmission by intravenous immunoglobulin","volume":"2","author":"Williams","year":"1988","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biologicals.2025.101849_bib136","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/biol.1994.1003","article-title":"Inactivation of hepatitis C virus in low pH intravenous immunoglobulin","volume":"22","author":"Louie","year":"1994","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2025.101849_bib137","series-title":"Transfusion microbiology","first-page":"259","article-title":"Fractionated products","author":"Foster","year":"2008"},{"issue":"11","key":"10.1016\/j.biologicals.2025.101849_bib138","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1111\/trf.16022","article-title":"Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics: 20 years\u02bc experience of the plasma protein manufacturers","volume":"60","author":"Roth","year":"2020","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.biologicals.2025.101849_bib139","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/bit.28017","article-title":"Virus filtration: a review of current and future practices in bioprocessing","volume":"119","author":"Johnson","year":"2022","journal-title":"Biotechnol Bioeng"},{"issue":"3","key":"10.1016\/j.biologicals.2025.101849_bib140","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.blre.2008.10.004","article-title":"Globalisation and blood safety","volume":"23","author":"Farrugia","year":"2009","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.biologicals.2025.101849_bib141","article-title":"Emerging and Re-Emerging viral diseases: the case of coronavirus Disease-19 (COVID-19)","volume":"7","author":"Abebe","year":"2020","journal-title":"Int J Virol AIDS"},{"issue":"9","key":"10.1016\/j.biologicals.2025.101849_bib142","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41558-022-01426-1","article-title":"Over half of known human pathogenic diseases can be aggravated by climate change","volume":"12","author":"Mora","year":"2022","journal-title":"Nat Clim Change"},{"issue":"10","key":"10.1016\/j.biologicals.2025.101849_bib143","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010843","article-title":"Transfusion-transmitted arboviruses: update and systematic review","volume":"16","author":"Gim\u00e9nez-Richarte","year":"2022","journal-title":"PLoS Neglected Trop Dis"},{"issue":"8","key":"10.1016\/j.biologicals.2025.101849_bib144","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1046\/j.1537-2995.2003.00496.x","article-title":"West nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data","volume":"43","author":"Kreil","year":"2003","journal-title":"Transfusion"},{"issue":"10","key":"10.1016\/j.biologicals.2025.101849_bib145","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1111\/j.1537-2995.2012.03565.x","article-title":"Chikungunya virus and the safety of plasma products","volume":"52","author":"Leydold","year":"2012","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.biologicals.2025.101849_bib146","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/trf.13343","article-title":"Hepatitis E virus and the safety of plasma products: investigations into the reduction capacity of manufacturing processes","volume":"56","author":"Farcet","year":"2016","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.biologicals.2025.101849_bib147","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/vox.13267","article-title":"Plasma procurement and plasma product safety in light of the COVID\u201019 pandemic from the perspective of the plasma industry","volume":"117","author":"Turecek","year":"2022","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2025.101849_bib148","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/trf.17801","volume":"64","author":"So-Osman","year":"2024","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.biologicals.2025.101849_bib149","first-page":"161","volume":"24","author":"Hegardt","year":"1968","journal-title":"Sodium Citrate Salting-out Human Blood Serum Proteins. jpb"},{"key":"10.1016\/j.biologicals.2025.101849_bib150","series-title":"Proceedings of the international workshop on technology for protein separation and improvement of blood plasma fractionation","first-page":"380","article-title":"Preparation of the major plasma fractions by solid-phase electrolytes","author":"Johnson","year":"1977"},{"key":"10.1016\/j.biologicals.2025.101849_bib151","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1477-044X-2-7","article-title":"Magnetic techniques for the isolation and purification of proteins and peptides","volume":"2","author":"Safarik","year":"2004","journal-title":"Biomagn Res Technol"},{"key":"10.1016\/j.biologicals.2025.101849_bib152","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.chroma.2009.11.034","article-title":"Aqueous two-phase systems: a viable platform in the manufacturing of biopharmaceuticals","volume":"1217","author":"Rosa","year":"2009","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.biologicals.2025.101849_bib153","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/btpr.1565","article-title":"Purification of IgG and albumin from human plasma by aqueous two phase system fractionation","volume":"28","author":"Vargas","year":"2012","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.biologicals.2025.101849_bib154","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.biologicals.2014.10.003","article-title":"Purification of equine whole IgG snake antivenom by using an aqueous two phase system as a primary purification step","volume":"43","author":"Vargas","year":"2015","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2025.101849_bib155","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.chroma.2007.03.067","article-title":"Affinity partitioning of human antibodies in aqueous two-phase systems","volume":"1162","author":"Rosa","year":"2007","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.biologicals.2025.101849_bib156","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/biot.201400532","article-title":"Partitioning in aqueous two-phase systems: analysis of strengths, weaknesses, opportunities and threats","volume":"10","author":"Soares","year":"2015","journal-title":"Biotechnol J"},{"key":"10.1016\/j.biologicals.2025.101849_bib157","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0021-9673(01)88579-4","article-title":"Cascade-mode multiaffinity chromatography. Fractionation of human serum proteins","volume":"550","author":"Porath","year":"1991","journal-title":"J Chromatogr."},{"key":"10.1016\/j.biologicals.2025.101849_bib158","volume":"vol. 5","author":"Uemura","year":"1992"},{"key":"10.1016\/j.biologicals.2025.101849_bib159","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1042\/bj2030637","article-title":"Chromatography of plasma proteins on cibacron blue F3-GA","volume":"203","author":"Gianazza","year":"1982","journal-title":"Biochem J"},{"key":"10.1016\/j.biologicals.2025.101849_bib160","article-title":"Sequential protein isolation and purification schemes by affinity chromatography","author":"Burton","year":"2006","journal-title":"Int Patent WO 2006\/0223831 A2"},{"key":"10.1016\/j.biologicals.2025.101849_bib161","unstructured":"Ryplazim - plasminogen injection. Prescribing Information. https:\/\/www.ryplazim.com\/pdf\/ryplazim-prescribing-information.pdf. Accessed 30.October.2024."},{"issue":"2","key":"10.1016\/j.biologicals.2025.101849_bib162","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1055\/s-0038-1655980","article-title":"Successful clinical use of a plasma-derived, dual virus inactivated factor VII concentrate incorporating solvent-detergent and dry heat treatment","volume":"77","author":"Smith","year":"1997","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.biologicals.2025.101849_bib163","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0049-3848(75)90039-0","article-title":"Purification and characterization of human factor IX","volume":"7","author":"Andersson","year":"1975","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.biologicals.2025.101849_bib164","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0049-3848(74)90001-2","article-title":"Purification of antithrombin III by affinity chromatography","volume":"5","author":"Miller-Andersson","year":"1974","journal-title":"Thromb Res"},{"key":"10.1016\/j.biologicals.2025.101849_bib165","article-title":"Cibacron blue dye removal from IEX media - BioProcess international","author":"Gupte","year":"2020","journal-title":"BioProcess Int"},{"issue":"1","key":"10.1016\/j.biologicals.2025.101849_bib166","doi-asserted-by":"crossref","DOI":"10.1002\/biot.201800397","article-title":"Affinity chromatography: an enabling technology for large-scale bioprocessing","volume":"15","author":"\u0141\u0105cki","year":"2020","journal-title":"Biotechnol J"},{"key":"10.1016\/j.biologicals.2025.101849_bib167","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.chroma.2017.01.031","article-title":"DNA aptamer affinity ligands for highly selective purification of human plasma-related proteins from multiple sources","volume":"1489","author":"Forier","year":"2017","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.biologicals.2025.101849_bib168","series-title":"Affinity chromatography","article-title":"Affinity chromatography for purification of IgG from human plasma","author":"Hofbauer","year":"2012"},{"issue":"22","key":"10.1016\/j.biologicals.2025.101849_bib169","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1002\/jssc.201200199","article-title":"Purification of polyclonal antibodies from cohn fraction II + III, skim milk, and whey by affinity chromatography using a hexamer peptide ligand","volume":"35","author":"Menegatti","year":"2012","journal-title":"J Separ Sci"},{"issue":"2","key":"10.1016\/j.biologicals.2025.101849_bib170","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/10826068.2024.2384494","article-title":"Quantification of human intravenous immunoglobulin from plasma and in process samples by affinity chromatography","volume":"55","author":"Mozgovicz","year":"2025","journal-title":"Prep Biochem Biotechnol"},{"key":"10.1016\/j.biologicals.2025.101849_bib171","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0167-7799(97)01045-7","article-title":"Expanded-bed adsorption in industrial bioprocessing: recent developments","volume":"15","author":"Hjorth","year":"1997","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.biologicals.2025.101849_bib172","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ab.2009.12.002","article-title":"A novel core fractionation process of human plasma by expanded bed adsorption chromatography","volume":"399","author":"Lihme","year":"2010","journal-title":"Anal Biochem"},{"key":"10.1016\/j.biologicals.2025.101849_bib173","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/vox.13388","article-title":"PlasmaCap EBA: an innovative method of isolating plasma proteins from human plasma","volume":"118","author":"Miller","year":"2023","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2025.101849_bib174","article-title":"A prospective, open-label, multicenter study of the efficacy, safety, tolerability, and pharmacokinetics of therapure PlasmaCap IG in adults and children with primary immune deficiency diseases","year":"2020","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.biologicals.2025.101849_bib175","series-title":"Proceedings of the international workshop on technology for protein separation and improvement of blood plasma fractionation","first-page":"441","article-title":"Continuous preparative electrophoresis \u2013 an overview, and new production scale system","author":"Thomson","year":"1977"},{"key":"10.1016\/j.biologicals.2025.101849_bib176","series-title":"Proceedings of the international workshop on technology for protein separation and improvement of blood plasma fractionation","first-page":"456","article-title":"Continuous preparative electrophoresis","author":"Bier","year":"1977"},{"key":"10.1016\/j.biologicals.2025.101849_bib177","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/elps.200406150","article-title":"Blood protein purification and simultaneous removal of nonenveloped viruses using tangential-flow preparative electrophoresis","volume":"26","author":"Evtushenko","year":"2005","journal-title":"Electrophoresis"},{"key":"10.1016\/j.biologicals.2025.101849_bib178","series-title":"Plasma protein fractionation by sequential polyacid precipitation","author":"Van Alstine","year":"2014"},{"key":"10.1016\/j.biologicals.2025.101849_bib179","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/bit.27265","article-title":"Polyacrylic acid based plasma fractionation for the production of albumin and IgG: compatibility with existing commercial downstream processes","volume":"117","author":"McCann","year":"2020","journal-title":"Biotechnol Bioeng"},{"issue":"3","key":"10.1016\/j.biologicals.2025.101849_bib180","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/0091270010372107","article-title":"Safety of plasma volume expanders","volume":"51","author":"Farrugia","year":"2011","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.biologicals.2025.101849_bib181","first-page":"CD000567","article-title":"Colloids versus crystalloids for fluid resuscitation in critically ill people","volume":"8","author":"Lewis","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.biologicals.2025.101849_bib182","series-title":"Annual update in intensive care and emergency medicine 2014","first-page":"395","article-title":"Albumin: therapeutic role in the current era","author":"Farrugia","year":"2014"},{"issue":"3","key":"10.1016\/j.biologicals.2025.101849_bib183","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/17511437241259437","article-title":"The efficacy, safety and effectiveness of hyperoncotic albumin solutions in patients with sepsis: a systematic review and meta-analysis","volume":"25","author":"Bannard-Smith","year":"2024","journal-title":"J Intensive Care Soc"},{"issue":"2","key":"10.1016\/j.biologicals.2025.101849_bib184","first-page":"1","article-title":"Recombinant versus plasma-derived human albumin: efficacy, safety, and future prospects in clinical medicine","volume":"2","author":"Wiedermann","year":"2024","journal-title":"Paracelsus Proceed Exper Med"},{"issue":"3","key":"10.1016\/j.biologicals.2025.101849_bib185","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.mam.2011.12.002","article-title":"Human serum albumin: from bench to bedside","volume":"33","author":"Fanali","year":"2012","journal-title":"Mol Aspect Med"},{"key":"10.1016\/j.biologicals.2025.101849_bib186","year":"2024","journal-title":"Recombinant Human Albumin (Liquid) - Anrate"},{"issue":"1245A","key":"10.1016\/j.biologicals.2025.101849_bib187","article-title":"Study of the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of recombinant human albumin in patients with ascites due to cirrhosis","volume":"74","author":"Li","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.biologicals.2025.101849_bib188","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1016\/S0168-8278(23)00752-3","article-title":"Combination of weekly albumin infusion, personalized nutrition and home-based exercise programme improves outcomes of patients with end stage liver disease (Al-Fit study)","volume":"78","author":"Kedarisetty","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.biologicals.2025.101849_bib189","first-page":"1","article-title":"Recombinant versus plasma-derived human albumin: efficacy, safety, and future prospects in clinical medicine","volume":"2","author":"Wiedermann","year":"2024","journal-title":"Paracelsus Proceed Exper Med"},{"issue":"3","key":"10.1016\/j.biologicals.2025.101849_bib190","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/bjh.16311","article-title":"Factor VIII: the protein, cloning its gene, synthetic factor and now \u2013 35 years later \u2013 gene therapy; what happened in between?","volume":"189","author":"Ling","year":"2020","journal-title":"Br J Haematol"},{"issue":"5879","key":"10.1016\/j.biologicals.2025.101849_bib191","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/299178a0","article-title":"Molecular cloning of the gene for human anti-haemophilic factor IX","volume":"299","author":"Choo","year":"1982","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.biologicals.2025.101849_bib192","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1055\/s-0033-1356715","article-title":"Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update","volume":"39","author":"Franchini","year":"2013","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"10.1016\/j.biologicals.2025.101849_bib193","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1111\/hae.13193","article-title":"Incidence of low-titre factor VIII inhibitors in patients with haemophilia A: meta-analysis of observational studies","volume":"23","author":"Messori","year":"2017","journal-title":"Haemophilia"},{"issue":"21","key":"10.1016\/j.biologicals.2025.101849_bib194","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in Hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.biologicals.2025.101849_bib195","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102461","article-title":"Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)","volume":"8","author":"Fischer","year":"2024","journal-title":"Res Practice Thrombosis and Haemostasis"},{"key":"10.1016\/j.biologicals.2025.101849_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101164","article-title":"Nothing short of a revolution: novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A","volume":"64","author":"Abdelgawad","year":"2024","journal-title":"Blood Rev"},{"key":"10.1016\/j.biologicals.2025.101849_bib197","first-page":"331","article-title":"The impact of emicizumab on the clinical validation of new therapies for haemophilia A. Haemophilia","volume":"31","author":"Hermans","year":"2024"},{"issue":"25","key":"10.1016\/j.biologicals.2025.101849_bib198","article-title":"Gene therapy for hemophilia - from basic science to first approvals of \u2018one-and-done\u2019 therapies","volume":"S1525\u20130016","author":"Herzog","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.biologicals.2025.101849_bib199","author":"Liu"},{"issue":"11","key":"10.1016\/j.biologicals.2025.101849_bib200","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40265-023-01912-6","article-title":"Concizumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.biologicals.2025.101849_bib201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymthe.2022.12.001","article-title":"First hemophilia B gene therapy approved: more than two decades in the making","volume":"31","author":"Herzog","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.biologicals.2025.101849_bib202","series-title":"Gene therapy hemgenix gains ground in Europe with Spanish reimbursement deal","author":"Schofield","year":"2024"},{"key":"10.1016\/j.biologicals.2025.101849_bib203","series-title":"Gene therapy hemgenix gains ground in Europe with Spanish reimbursement deal","author":"Schofield","year":"2024"},{"key":"10.1016\/j.biologicals.2025.101849_bib204","author":"Liu"},{"issue":"4","key":"10.1016\/j.biologicals.2025.101849_bib205","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40265-024-02017-4","article-title":"Fidanacogene elaparvovec: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.biologicals.2025.101849_bib207","author":"Lobo"},{"issue":"Supplement 1","key":"10.1016\/j.biologicals.2025.101849_bib208","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/blood-2022-159631","article-title":"Serpinpc in persons with severe Hemophilia (PwH): updated results from a multi-center, multi-part, first-in-human study","volume":"140","author":"Baglin","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.biologicals.2025.101849_bib209","doi-asserted-by":"crossref","DOI":"10.5582\/ddt.2025.01031","article-title":"Fitusiran: the first approved siRNA therapy for hemophilia via reducing plasma antithrombin levels","author":"Lu","year":"2025","journal-title":"Drug Discov Ther"},{"issue":"1","key":"10.1016\/j.biologicals.2025.101849_bib210","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.clinthera.2024.11.020","article-title":"Hympavzi (Marstacimab-hncq)","volume":"47","author":"Beninger","year":"2025","journal-title":"Clin Ther"},{"issue":"9","key":"10.1016\/j.biologicals.2025.101849_bib211","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/bloodadvances.2019000849","article-title":"Laboratory monitoring of hemophilia A treatments: new challenges","volume":"4","author":"Lenting","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.biologicals.2025.101849_bib212","unstructured":"Anandani G, Patel T, Parmar R. The implication of new developments in hemophilia treatment on its laboratory evaluation. Cureus. 14(10):e30212."},{"issue":"S3","key":"10.1016\/j.biologicals.2025.101849_bib213","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/hae.14976","article-title":"Benefits and risks of non-factor therapies: redefining haemophilia treatment goals in the era of new technologies","volume":"30","author":"Mancuso","year":"2024","journal-title":"Haemophilia"},{"issue":"S3","key":"10.1016\/j.biologicals.2025.101849_bib214","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/hae.14976","article-title":"Benefits and risks of non-factor therapies: redefining haemophilia treatment goals in the era of new technologies","volume":"30","author":"Mancuso","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.biologicals.2025.101849_bib215","series-title":"World Federation of hemophilia","article-title":"Annual global survey 2023","year":"2023"},{"issue":"10","key":"10.1016\/j.biologicals.2025.101849_bib216","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102366","article-title":"Next-generation Fc receptor-targeting biologics for autoimmune diseases","volume":"18","author":"Zuercher","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.biologicals.2025.101849_bib217","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00580","article-title":"Advances in therapeutic Fc engineering \u2013 modulation of IgG-Associated effector functions and serum half-life","volume":"7","author":"Saxena","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.biologicals.2025.101849_bib218","article-title":"Fc multimers effectively treat murine models of multiple sclerosis","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.biologicals.2025.101849_bib219","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3390\/jcm10051004","article-title":"Emerging therapies in immune thrombocytopenia","volume":"10","author":"Audia","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.biologicals.2025.101849_bib220","series-title":"Phase 2 clinical proof-of-concept trial of ARGX-113 (Efgartigimod) in generalized myasthenia gravis","year":"2017"},{"issue":"1","key":"10.1016\/j.biologicals.2025.101849_bib221","article-title":"Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis","volume":"14","author":"Ma","year":"2024","journal-title":"Sci Rep"},{"issue":"14","key":"10.1016\/j.biologicals.2025.101849_bib222","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s40265-023-01933-1","article-title":"Rozanolixizumab: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.biologicals.2025.101849_bib223","author":"Kimmel"},{"issue":"8","key":"10.1016\/j.biologicals.2025.101849_bib224","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/s41587-021-00894-8","article-title":"Generation of recombinant hyperimmune globulins from diverse B-cell repertoires","volume":"39","author":"Keating","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.biologicals.2025.101849_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105902","article-title":"New technologies in therapeutic antibody development: the next frontier for treating infectious diseases","volume":"227","author":"Keating","year":"2024","journal-title":"Antivir Res"},{"issue":"9","key":"10.1016\/j.biologicals.2025.101849_bib226","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/17474086.2016.1214070","article-title":"Von Willebrand factor (Vonvendi\u00ae): the first recombinant product licensed for the treatment of von Willebrand disease","volume":"9","author":"Franchini","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"10.1016\/j.biologicals.2025.101849_bib227","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/ACI.0000000000001042","article-title":"Hereditary angioedema due to C1-inhibitor deficiency: current therapeutic approaches","volume":"24","author":"Costanzo","year":"2024","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.biologicals.2025.101849_bib228","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.coph.2021.06.001","article-title":"Alpha1-antitrypsin deficiency: new therapies on the horizon","volume":"59","author":"Remih","year":"2021","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"10.1016\/j.biologicals.2025.101849_bib229","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000464168","volume":"40","author":"Finlayson","year":"1981","journal-title":"Vox Sang"},{"issue":"6","key":"10.1016\/j.biologicals.2025.101849_bib230","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1423-0410.1983.tb03662.x","article-title":"What is the prospective impact of the recombinant DNA technique on the production of human plasma derivatives? Which are the derivates where donor plasma could be replaced?","volume":"44","author":"Aledort","year":"1983","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2025.101849_bib231","series-title":"Production of plasma proteins for therapeutic use","first-page":"3","article-title":"The history and development of the plasma protein fractionation industry","author":"Curling","year":"2013"},{"key":"10.1016\/j.biologicals.2025.101849_bib232","series-title":"The supply of plasma-derived medicinal products in the future of Europe","article-title":"The global demand for PDMPs: current scenario and future trends","author":"Robert","year":"2024"},{"key":"10.1016\/j.biologicals.2025.101849_bib233","author":"Krever"},{"key":"10.1016\/j.biologicals.2025.101849_bib234","series-title":"HIV and the blood supply: an analysis of crisis decisionmaking","year":"1995"},{"issue":"Suppl 1","key":"10.1016\/j.biologicals.2025.101849_bib235","first-page":"1","article-title":"Disease transmission by blood products: past, present and future","volume":"32","author":"Murphy","year":"2002","journal-title":"Pathophysiol Haemostasis Thrombosis"},{"issue":"22","key":"10.1016\/j.biologicals.2025.101849_bib236","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.jacc.2024.03.396","article-title":"Effect of reconstituted human apolipoprotein A-I on recurrent ischemic events in survivors of acute MI","volume":"83","author":"Povsic","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.biologicals.2025.101849_bib238","first-page":"345","article-title":"Trialing plasma protein therapies for rare disorders: thinking outside the box","volume":"11","author":"Farrugia","year":"2009","journal-title":"Pharm Policy Law"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105625000405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105625000405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T06:12:32Z","timestamp":1755670352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105625000405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":235,"alternative-id":["S1045105625000405"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2025.101849","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The past, present and future of blood plasma fractionation","name":"articletitle","label":"Article Title"},{"value":"Biologicals","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biologicals.2025.101849","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of International Alliance for Biological Standardization.","name":"copyright","label":"Copyright"}],"article-number":"101849"}}